Microenvironment crosstalk and immune evasion of circulating tumor cells: From mechanism to clinical significance.

Chin Med J (Engl)

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Circulating tumor cells (CTCs), shed from the primary malignancies, are regarded as the "seeds" of tumor metastasis. They employ sophisticated strategies to evade immune detection during blood circulation by engaging with various blood components, ultimately facilitating their colonization in distant organs. Elucidating the mechanisms underlying CTC immune evasion may unlock novel immunotherapeutic strategies to prevent tumor metastasis. Recent advancements in CTC isolation and single-cell sequencing have provided insights into their complex microenvironment and immune evasion mechanisms. Many strategies for targeting either CTCs or their associated blood cells have been explored. Here, we systematically delineated the interaction network between CTCs and the diverse blood cells. By elucidating the microenvironmental and biological characteristics of CTCs, we summarize several potential immune evasion mechanisms, including immune checkpoint modulation, CTC clustering, platelet interactions, etc. Additionally, we highlight recent advances in intervention strategies targeting CTCs and the clinical application of CTCs in cancer liquid biopsy.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CM9.0000000000003738DOI Listing

Publication Analysis

Top Keywords

immune evasion
16
circulating tumor
8
tumor cells
8
tumor metastasis
8
evasion mechanisms
8
strategies targeting
8
targeting ctcs
8
blood cells
8
immune
6
ctcs
6

Similar Publications

Leishmania parasite adeptly evades the host's immune defences by infiltrating macrophages, exploiting apoptotic processes for further dissemination. Among the host's strategies to counter parasitic propagation, the pivotal role of B-cells, specifically B regulatory (Breg) cells, emerges. Recent evidence from in vitro and in vivo studies has thrust Breg cells into the spotlight, attributed to their IL-10 secretion and antigen presentation.

View Article and Find Full Text PDF

Malignant tumors present a major global health burden, as they generally have a poor prognosis, and the efficacy of available treatments is limited. Copine family members (CPNEs) play crucial roles in the regulation of tumor cell proliferation, metastasis, and therapeutic resistance, as well as in tumor diagnosis and prognostic risk stratification. CPNEs can facilitate tumor cell survival by regulating cell cycle progression and cell death.

View Article and Find Full Text PDF

Glycoside hydrolase Ma3360 mediates immune evasion by Metarhizium anisopliae in insects.

Pestic Biochem Physiol

November 2025

National Key Laboratory of Green Pesticide, College of Plant Protection, South China Agricultural University, Guangzhou 510642, China. Electronic address:

Entomopathogenic fungi can precisely inhibit the cellular and humoral immune responses of host insects by secreting effector proteins, allowing them to overcome the innate immune barriers of their hosts. Nodule formation is an immune response primarily mediated by insect hemocytes, which can rapidly and efficiently capture invading pathogenic fungi in the hemocoel. However, the molecular mechanisms by which fungi inhibit insect nodule formation through the secretion of effector proteins remain unclear.

View Article and Find Full Text PDF

KRAS mutations in Non-Small Cell Lung Cancer: translational aspects, current therapies and challenges for future research.

Crit Rev Oncol Hematol

September 2025

Unit of Cancer Genetics, Institute of Genetic & Biomedical Research (IRGB), National Research Council (CNR), Traversa La Crucca n. 3, 07100, Sassari, Italy; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari, Viale San Pietro 43, 07100, Sassari, Italy. Electronic address: gpalmier

Mutations in the KRAS gene are prominent oncogenic drivers in non-small cell lung cancer (NSCLC), with multiple pathophysiological, clinical and prognostic implications. Although historically considered an "undruggable" target, recent research led to the development of specific KRAS-G12C inhibitors, like sotorasib and adagrasib which are currently approved for clinical use in patients affected by advanced NSCLC. However, the clinical utility of these drugs is often limited by resistance development through several biological mechanisms, including additional KRAS mutations, activation of compensatory pathways and metabolic reprogramming.

View Article and Find Full Text PDF

Role of PAI-1 in the progression and treatment resistance of non-small cell lung cancer.

Biomed J

September 2025

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University. Electronic address:

Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Although immune checkpoint inhibitors (ICIs), chemotherapy, and molecular targeted therapies have improved survival rates, therapeutic resistance remains a major barrier to curative outcomes. Recently, plasminogen activator inhibitor-1 (PAI-1) has been implicated in lung cancer progression and treatment resistance.

View Article and Find Full Text PDF